Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.
Guselkumab Safety in Patients With Latent Tuberculosis: Analysis of 11 Studies in Psoriatic Disease.
Journal: The Journal of dermatology
Published: February 04, 2026
Icotrokinra induces early and sustained pharmacodynamic responses in phase IIb study of patients with moderate-to-severe psoriasis.
Journal: JCI insight
Published: April 07, 2025
Guselkumab Efficacy by Psoriasis Disease Severity and Treatment History: VOYAGE 1 and 2 Post Hoc Analyses.
Journal: Journal of drugs in dermatology : JDD
Published: February 06, 2025
Patients with Persistent Mild Psoriasis after Treatment with Ustekinumab Achieved Greater Improvements in Skin Clearance and Patient-reported Outcomes after Switching to Guselkumab in the Phase 3 NAVIGATE Trial.
Journal: Acta dermato-venereologica
Published: June 24, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation Analysis.
Journal: Dermatology and therapy
Published: May 01, 2024
Long-Term Safety of Guselkumab in Patients with Psoriatic Disease: An Integrated Analysis of Eleven Phase II/III Clinical Studies in Psoriasis and Psoriatic Arthritis.
Journal: Drug safety
Published: October 04, 2023
Support for Caregivers of Patients With Cancer: An Experiential Mind-Body Approach to Self-Care.
Journal: Clinical journal of oncology nursing
Published: September 20, 2023
Residual Lesional Gene Expression in Psoriasis Patients with Complete Skin Clearance Treated with Guselkumab or Adalimumab in VOYAGE 1 and 2.
Journal: The Journal of investigative dermatology
Published: March 14, 2023
Guselkumab for the treatment of patients with moderate-to-severe hidradenitis suppurativa: A phase 2 randomized study.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV
Published: January 20, 2023
Safety of guselkumab treatment for up to 5 years in patients with moderate-to-severe psoriasis: pooled analyses across seven clinical trials with more than 8600 patient-years of exposure.
Journal: The British journal of dermatology
Published: January 19, 2023
Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials.
Journal: The British journal of dermatology
Published: January 13, 2023
Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials.
Journal: Journal of the American Academy of Dermatology
Published: January 04, 2023
Last Updated: 09/26/2026